Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 18

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Jun 26, 2022; 10(18): 6110-6118
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6110

Full Size Figure Download Figure

Figure 3 Cutaneous toxicities continued to worsen, and extensive skin ulceration was observed.

Citation: Wu JY, Kang K, Yi J, Yang B. Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature. World J Clin Cases 2022; 10(18): 6110-6118
URL: https://www.wjgnet.com/2307-8960/full/v10/i18/6110.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i18.6110

Wu JY, Kang K, Yi J, Yang B. Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature. World J Clin Cases 2022; 10(18): 6110-6118 [PMID: 35949835 DOI: 10.12998/wjcc.v10.i18.6110]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.